Zika Virus Replicons for Drug Discovery

Xuping Xie, Jing Zou, Chao Shan, Yujiao Yang, Dieudonné Buh Kum, Kai Dallmeier, Johan Neyts, Pei Yong Shi

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

The current epidemic of Zika virus (ZIKV) has underscored the urgency to establish experimental systems for studying viral replication and pathogenesis, and countermeasure development. Here we report two ZIKV replicon systems: a luciferase replicon that can differentiate between viral translation and RNA synthesis; and a stable luciferase replicon carrying cell line that can be used to screen and characterize inhibitors of viral replication. The transient replicon was used to evaluate the effect of an NS5 polymerase mutation on viral RNA synthesis and to analyze a known ZIKV inhibitor. The replicon cell line was developed into a 96-well format for antiviral testing. Compare with virus infection-based assay, the replicon cell line allows antiviral screening without using infectious virus. Collectively, the replicon systems have provided critical tools for both basic and translational research.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalEBioMedicine
Volume12
DOIs
StatePublished - Oct 1 2016

Keywords

  • Drug discovery
  • Flavivirus
  • Replicon
  • Zika

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Zika Virus Replicons for Drug Discovery'. Together they form a unique fingerprint.

  • Cite this

    Xie, X., Zou, J., Shan, C., Yang, Y., Kum, D. B., Dallmeier, K., Neyts, J., & Shi, P. Y. (2016). Zika Virus Replicons for Drug Discovery. EBioMedicine, 12, 156-160. https://doi.org/10.1016/j.ebiom.2016.09.013